Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers

BACKGROUND: Tumor mutational burden (TMB) may be a predictive biomarker of immune checkpoint inhibitor (ICI) responsiveness. Genomic landscape heterogeneity is a well-established cancer feature. Molecular characteristics may differ even within the same tumor specimen and undoubtedly evolve with time...

Descripción completa

Detalles Bibliográficos
Autores principales: Pham, Timothy V., Goodman, Aaron M., Sivakumar, Smruthy, Frampton, Garrett, Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513181/
https://www.ncbi.nlm.nih.gov/pubmed/34641956
http://dx.doi.org/10.1186/s13073-021-00979-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513181/
https://www.ncbi.nlm.nih.gov/pubmed/34641956
http://dx.doi.org/10.1186/s13073-021-00979-8

Ejemplares similares